AXIM BIOTECHNOLOGIES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AXIM BIOTECHNOLOGIES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $39.5K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $8.9K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $60.5K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 19, 2022 |
| FY2019 | Dec 31, 2019 | $799.5K | May 20, 2020 |
| FY2019 | Dec 31, 2018 | $195.6K | May 20, 2020 |
| FY2018 | Dec 31, 2017 | $47.6K | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | $47.1K | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $49.1K | Sep 14, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Apr 18, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Apr 26, 2021 |
| FY2020 | Dec 31, 2019 | $0 | Apr 26, 2021 |
| FY2019 | Dec 31, 2018 | $187.1K | May 20, 2020 |
| FY2018 | Dec 31, 2017 | $4.7K | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | ($107.1K) | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | ($1.2K) | Sep 14, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Apr 18, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($8.06M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($6.24M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($16.03M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($6.41M) | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | ($6.45M) | Apr 26, 2021 |
| FY2019 | Dec 31, 2018 | ($6.75M) | May 20, 2020 |
| FY2018 | Dec 31, 2017 | ($4.17M) | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | ($5.81M) | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | ($10.09M) | Sep 14, 2017 |
| FY2015 | Dec 31, 2014 | ($582.9K) | Apr 18, 2016 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($2.75M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($4.65M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($13.97M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($4.95M) | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | ($3.11M) | Apr 26, 2021 |
| FY2019 | Dec 31, 2018 | ($5.04M) | May 20, 2020 |
| FY2018 | Dec 31, 2017 | ($3.15M) | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | ($3.76M) | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | ($10.05M) | Sep 14, 2017 |
| FY2015 | Dec 31, 2014 | ($505.7K) | Apr 18, 2016 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $125.5K | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $153.7K | Apr 16, 2024 |
| FY2023 | Dec 31, 2021 | $284.9K | Apr 16, 2024 |
| FY2021 | Dec 31, 2020 | $426.7K | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Apr 26, 2021 |
| FY2019 | Dec 31, 2018 | $2.06M | May 20, 2020 |
| FY2018 | Dec 31, 2017 | $1.35M | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | $235.6K | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $571.5K | Sep 14, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Apr 18, 2016 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $2.24M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $4.08M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $5.67M | Apr 17, 2023 |
| FY2016 | Dec 31, 2016 | $3.41M | Sep 14, 2017 |
| FY2016 | Dec 31, 2015 | $9.48M | Sep 14, 2017 |
| FY2015 | Dec 31, 2014 | $505.7K | Apr 18, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($1.03M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($2.04M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($2.49M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($3.22M) | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | ($5.04M) | Apr 26, 2021 |
| FY2016 | Dec 31, 2016 | ($1.29M) | Sep 14, 2017 |
| FY2016 | Dec 31, 2015 | ($1.54M) | Sep 14, 2017 |
| FY2015 | Dec 31, 2014 | ($339.0K) | Apr 18, 2016 |
| FY2014 | Dec 31, 2013 | ($33.0K) | Apr 14, 2015 |
| FY2012 | Dec 31, 2012 | $21.1K | Apr 15, 2013 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $8.7K | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $40.5K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $97.3K | Apr 19, 2022 |
| FY2016 | Dec 31, 2016 | $0 | Sep 14, 2017 |
| FY2016 | Dec 31, 2015 | ($16.8K) | Sep 14, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Apr 18, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $4.12M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $4.21M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $5.32M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $11.31M | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | $1.69M | Apr 26, 2021 |
| FY2019 | Dec 31, 2018 | $2.09M | May 20, 2020 |
| FY2018 | Dec 31, 2017 | $2.19M | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | $1.45M | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $1.26M | Sep 14, 2017 |
| FY2015 | Dec 31, 2014 | $738.5K | Apr 18, 2016 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $11.78M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | $9.04M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | $7.66M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $9.75M | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | $8.45M | Apr 26, 2021 |
| FY2019 | Dec 31, 2018 | $8.17M | May 20, 2020 |
| FY2018 | Dec 31, 2017 | $8.48M | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | $3.82M | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $2.96M | Sep 14, 2017 |
| FY2015 | Dec 31, 2014 | $1.32M | Apr 18, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($7.66M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($4.83M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2021 | ($2.34M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2020 | $1.57M | Apr 17, 2023 |
| FY2021 | Dec 31, 2019 | ($6.76M) | Apr 19, 2022 |
| FY2016 | Dec 31, 2016 | ($2.37M) | Sep 14, 2017 |
| FY2016 | Dec 31, 2015 | ($1.70M) | Sep 14, 2017 |
| FY2015 | Dec 31, 2014 | ($580.7K) | Apr 18, 2016 |
| FY2014 | Dec 31, 2013 | ($93.9K) | Apr 14, 2015 |
| FY2013 | Dec 31, 2012 | ($4.7K) | Mar 4, 2014 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Apr 19, 2022 |
| FY2021 | Dec 31, 2020 | $2.46M | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Apr 26, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($72.18M) | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | ($64.13M) | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | ($57.88M) | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | ($41.85M) | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | ($35.44M) | Apr 26, 2021 |
| FY2019 | Dec 31, 2018 | ($28.99M) | May 20, 2020 |
| FY2018 | Dec 31, 2017 | ($22.24M) | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | ($18.07M) | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | ($10.78M) | Sep 14, 2017 |
| FY2015 | Dec 31, 2014 | ($692.0K) | Apr 18, 2016 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $47.3K | Apr 17, 2023 |
| FY2022 | Dec 31, 2021 | $453.0K | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $457.2K | Apr 19, 2022 |
| FY2021 | Dec 31, 2019 | $511.6K | Apr 19, 2022 |
| FY2020 | Dec 31, 2018 | $1.81M | Apr 26, 2021 |
| FY2019 | Dec 31, 2017 | $2.06M | May 20, 2020 |
| FY2018 | Dec 31, 2016 | $713.3K | Apr 8, 2019 |
| FY2017 | Dec 31, 2015 | $134.2K | Mar 15, 2018 |
| FY2015 | Dec 31, 2014 | $661.1K | Apr 18, 2016 |
| FY2015 | Dec 31, 2013 | $127 | Apr 18, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Apr 26, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Apr 26, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 245.93M | Apr 16, 2024 |
| FY2023 | Dec 31, 2022 | 192.44M | Apr 16, 2024 |
| FY2022 | Dec 31, 2021 | 138.10M | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | 125.33M | Apr 19, 2022 |
| FY2020 | Dec 31, 2019 | 64.85M | Apr 26, 2021 |
| FY2019 | Dec 31, 2018 | 59.58M | May 20, 2020 |
| FY2018 | Dec 31, 2017 | 54.56M | Apr 8, 2019 |
| FY2017 | Dec 31, 2016 | 52.51M | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | 39.63M | Sep 14, 2017 |
| FY2015 | Dec 31, 2014 | 33.00M | Apr 18, 2016 |